<DOC>
	<DOCNO>NCT02489604</DOCNO>
	<brief_summary>This randomized phase II non-comparative study . Patients gastroenteropancreatic Neuroendocrine tumour ( GEP-NET ) G1-G2 progressive disease , SSR positive FDG negative enrol study randomly assign 2 different dosage ( total activity 25.9 GBq total activity 18.5 GBq ) .</brief_summary>
	<brief_title>Peptide Receptor Radionuclide Therapy ( PRRT ) With 177Lu-DOTATATE Advanced Gastro-entero Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>This randomized phase II non-comparative study . Patients GEP-NET G1-G2 progressive disease , somatostatin receptor ( SSR ) positive FDG negative enrol study randomly assign 2 different dosage ( total activity 25.9 GBq total activity 18.5 GBq ) . The two level dosage : 1 . Total activity 25.9 GBq 100 mCi 7 cycle 6 ± 2 week ( 700 mCi ) 2 . Total activity 18.5 GBq 100 mCi 5 cycle 6 ± 2 week ( 500 mCi ) The randomize study design allow two active treatment evaluate comparable patient population . The estimate primary objective evaluate regimen separately Bryant Day design . While sample size power statistical test specific hypothesis comparison group , study design allow unbiased collection activity safety two regimen population , useful planning future study .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patients must histologically cytologically confirmation GEP NETand Ki 67 index &lt; = 20 % . Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1.criteria ) Advanced GEPNET eligible ; patient must progressive disease base RECIST 1.1. criterion Diagnostic OctreoScan and/or PET/CT 68Gapeptide image demonstrate significant uptake tumour FDG PET negative ( SUV less 2.5 ) Concomitant somatostatin analog assumption allow Life expectancy great 6 month . ECOG performance status &lt; 2 Adequate haematological , liver renal function : haemoglobin &gt; = 9 g/dL , absolute neutrophil count ( ANC ) &gt; = 1.5 x 109 /L , platelets &gt; = 100 x 109 /L , bilirubin ≤1.5 X upper normal limit ( UNL ) , Alanine transaminase ( ALT ) &lt; 2.5 X UNL ( &lt; 5 X UNL presence liver metastasis ) , creatinine &lt; 2 mg/dL . If female childbearing potential , agreement use adequate contraceptive method ( e.g. , oral contraceptive , condom , adequate barrier control , intrauterine contraceptive device , sterilization ) begin screen visit continue 3 month follow last treatment study drug . Negative serum pregnancy test female childbearing potential within 14 day start treatment . Participant willing able give inform consent participation study . Ki 67 index &gt; 20 % FDG PET positive least one document lesion SUV 2.5 Patients treat chemotherapy therapeutic radiotherapy within 4 week treat within 2 week palliative radiotherapy , hormonal biological therapy ) . Patients treat previous radiometabolic therapy adsorb dose kidney 25 Gy 1,5 Gy bone marrow . All acute toxic effect prior therapy ( include surgery radiation therapy , chemotherapy ) must resolve grade &lt; = 1 accord National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 ( CTCAE ) Participation another clinical trial investigational agent within 30 day prior study screen . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . History allergic reaction attribute compound similar chemical biologic composition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neuroendocrine tumor</keyword>
</DOC>